These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35908234)

  • 1. Consensus statement on the current pharmacological prevention and management of heart failure.
    Sindone AP; De Pasquale C; Amerena J; Burdeniuk C; Chan A; Coats A; Hare DL; Macdonald P; Sverdlov A; Atherton JJ
    Med J Aust; 2022 Aug; 217(4):212-217. PubMed ID: 35908234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.
    Tsutsui H
    Pharmacol Ther; 2022 Oct; 238():108185. PubMed ID: 35413307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.
    Mullens W; Martens P; Testani JM; Tang WHW; Skouri H; Verbrugge FH; Fudim M; Iacoviello M; Franke J; Flammer AJ; Palazzuoli A; Barragan PM; Thum T; Marcos MC; Miró Ò; Rossignol P; Metra M; Lassus J; Orso F; Jankowska EA; Chioncel O; Milicic D; Hill L; Seferovic P; Rosano G; Coats A; Damman K
    Eur J Heart Fail; 2022 Apr; 24(4):603-619. PubMed ID: 35239201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
    Peters AE; DeVore AD
    Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects.
    Lee MMY; Sattar N
    Diabetes Obes Metab; 2023 Jul; 25 Suppl 3():33-47. PubMed ID: 37041663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New therapeutic options in heart failure: the importance of the left ventricular ejection fraction].
    Nielsen Gerlach CL; Rutten FH; Mosterd A
    Ned Tijdschr Geneeskd; 2022 Nov; 166():. PubMed ID: 36633029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y; Kuwahara K
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A year in heart failure: an update of recent findings.
    Stretti L; Zippo D; Coats AJS; Anker MS; von Haehling S; Metra M; Tomasoni D
    ESC Heart Fail; 2021 Dec; 8(6):4370-4393. PubMed ID: 34918477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin: A Review in Symptomatic Chronic Heart Failure.
    Frampton JE
    Drugs; 2022 Nov; 82(16):1591-1602. PubMed ID: 36374374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial).
    Jariwala P; Jadhav K; Punjani A; Boorugu H; Mari AR
    Indian Heart J; 2021; 73(5):605-611. PubMed ID: 34627577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.
    Bauersachs J; de Boer RA; Lindenfeld J; Bozkurt B
    Eur Heart J; 2022 Feb; 43(5):367-376. PubMed ID: 34974611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dapagliflozin in DELIVER : confirmation of the benefit with SGLT2 inhibitors in heart failure with preserved ejection fraction].
    Scheen A; Lancellotti P
    Rev Med Liege; 2023 Feb; 78(2):79-84. PubMed ID: 36799324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.
    Packer M; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Anker SD; Zannad F;
    Eur J Heart Fail; 2019 Oct; 21(10):1270-1278. PubMed ID: 31584231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.
    Genuardi MV; Mather PJ
    Ther Adv Cardiovasc Dis; 2021; 15():17539447211002678. PubMed ID: 33779401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions.
    Lan NSR; Fegan PG; Yeap BB; Dwivedi G
    ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.